![Luis Sanay](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Luis Sanay is Vice President-Investor Relations at Altimmune, Inc. since 2026.
Formerly, Mr. Sanay was Head-Investor Relations at Novavax, Inc. from 2024 to 2026 and Head-Investor Relations at Harmony Biosciences Holdings, Inc. from 2022 to 2024.
Actieve functies van Luis Sanay
| Bedrijven | Functie | Begin |
|---|---|---|
| ALTIMMUNE, INC. | Investor Relations Contact | 01-03-2026 |
Eerdere bekende functies van Luis Sanay
| Bedrijven | Functie | Einde |
|---|---|---|
| NOVAVAX, INC. | Investor Relations Contact | 01-03-2026 |
| HARMONY BIOSCIENCES HOLDINGS, INC. | Investor Relations Contact | 01-09-2024 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
34
Eerstegraads connecties
3
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
Novavax, Inc.
 Novavax, Inc. BiotechnologyHealth Technology Engages in development of novel recombinant vaccines | Health Technology |
Altimmune, Inc.
 Altimmune, Inc. BiotechnologyHealth Technology Develops biopharmaceuticals | Health Technology |
Harmony Biosciences Holdings, Inc.
 Harmony Biosciences Holdings, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapies for patients living with rare neurological disorders | Health Technology |
